- Home
- SOPH vs NYXH Comparison
SOPH vs NYXH Comparison
Compare SOPH & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- NYXH
- Stock Information
- Founded
- SOPH 2011
- NYXH 2009
- Country
- SOPH Switzerland
- NYXH Belgium
- Employees
- SOPH N/A
- NYXH N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- NYXH Medical/Dental Instruments
- Sector
- SOPH Health Care
- NYXH Health Care
- Exchange
- SOPH Nasdaq
- NYXH Nasdaq
- Market Cap
- SOPH 231.8M
- NYXH 188.1M
- IPO Year
- SOPH 2021
- NYXH 2021
- Fundamental
- Price
- SOPH $4.52
- NYXH $4.99
- Analyst Decision
- SOPH
- NYXH Strong Buy
- Analyst Count
- SOPH 0
- NYXH 3
- Target Price
- SOPH N/A
- NYXH $15.00
- AVG Volume (30 Days)
- SOPH 144.5K
- NYXH 41.1K
- Earning Date
- SOPH 11-04-2025
- NYXH 11-13-2025
- Dividend Yield
- SOPH N/A
- NYXH N/A
- EPS Growth
- SOPH N/A
- NYXH N/A
- EPS
- SOPH N/A
- NYXH N/A
- Revenue
- SOPH $73,297,000.00
- NYXH $5,793,306.00
- Revenue This Year
- SOPH $16.60
- NYXH $85.62
- Revenue Next Year
- SOPH $19.09
- NYXH $320.09
- P/E Ratio
- SOPH N/A
- NYXH N/A
- Revenue Growth
- SOPH 13.66
- NYXH 2.94
- 52 Week Low
- SOPH $2.58
- NYXH $4.35
- 52 Week High
- SOPH $5.30
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- SOPH 53.20
- NYXH 38.66
- Support Level
- SOPH $4.01
- NYXH $4.95
- Resistance Level
- SOPH $5.11
- NYXH $5.96
- Average True Range (ATR)
- SOPH 0.39
- NYXH 0.25
- MACD
- SOPH 0.02
- NYXH -0.07
- Stochastic Oscillator
- SOPH 49.68
- NYXH 5.61
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.